Syndax Pharmaceuticals, Inc.
NASDAQ:SNDXBiotechnology
+$0.13 today
- Market cap
- $770.64M
- Beta
- 0.39
- P/E (TTM)
- -6.8
- EPS (TTM)
- -$2.81
Volume 3.46M
Average 1.70M
SNDX Common Stock Issued
Cash raised by issuing new shares.
Syndax Pharmaceuticals, Inc.NASDAQ: SNDX
Common Stock Issued · Q1 FY2026 · quarter ended Mar 2026
Common stock issued outflow grows to $7.92M
Q1 FY2026 common stock issued was $7.92M, compared with $0 a year earlier. Trailing-twelve-month common stock issued was $20.66M. Over 3 fiscal years it compounded at -57.8% a year.
Context
- Common stock issued amounted to 7.9% of revenue in FY2025, down 33.1 pp from a year earlier.
- Common stock issued increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly common stock issued holds near $7.92M or moves back toward the trailing-twelve-month quarterly average of $5.17M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Common Stock Issued history
USD · from the cash flow
- Latest · FY2025
- 13.68M USD
- Year-over-year change
- +40.8%
- 4-year CAGR
- -36.9%
| Period | Period end | Common Stock Issued | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.68M | +40.8% |
| FY2024 | 2024-12-31 | 9.72M | -96.2% |
| FY2023 | 2023-12-31 | 258.09M | +42.3% |
| FY2022 | 2022-12-31 | 181.39M | +110.1% |
| FY2021 | 2021-12-31 | 86.34M | — |
Common Stock Issued vs competitors
How SNDX compares with its peers on the latest reported figures
- SNDX's LTM Mar 2026 common stock issued of $20.66M is the 8th largest of the 11 companies compared; the peer median is $82.14M.
- Common stock issued amounts to 9.5% of revenue for SNDX, versus a peer median of 8.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $344.93M | +4714.1% | +454.4% | 970.5% | |
| LTM Jun 2026 | $313M | +108.7% | +167.2% | 267.5% | |
| LTM Mar 2026 | $308M | +17301.2% | +114.8% | — | |
| LTM Aug 2026 | $261.21M | +29.5% | +130.8% | 37.2% | |
| LTM Mar 2026 | $142.56M | +5475.6% | +24.1% | — | |
| LTM Dec 2025 | $85.85M | -134.0% | +183.1% | — | |
| LTM Sep 2026 | $21.71M | +31.3% | -39.9% | 8.2% | |
| LTM Mar 2026 | $20.66M | — | -57.8% | 9.5% | |
| LTM Jun 2026 | $8.3M | -95.7% | — | 7.9% | |
| LTM Jun 2026 | $4.36M | +236.8% | — | 2.6% | |
| LTM Mar 2026 | $140K | -82.4% | -50.8% | 0.1% | |
| Peer median (excluding SNDX) | $82.14M | +70.0% | +122.8% | 8.2% | |
Competitors are the stored peer set for SNDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 24.93M | (149.34M) | (209.36M) | (318.76M) | (285.42M) |
| Depreciation & Amortization | 43K | 33K | 12K | 8K | 6K |
| Deferred Income Tax | 255K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 13.32M | 16.02M | 30.95M | 43.03M | 47.5M |
| Change in Working Capital | (9.6M) | 1.66M | 31.86M | 13.27M | (79.32M) |
| Accounts Receivables | 0 | (3.47M) | 10.71M | (11.24M) | (36.83M) |
| Inventory | 0 | 3.47M | 0 | (366K) | (32.09M) |
| Accounts Payables | 2.16M | (1.32M) | 5.61M | 1.67M | 4.95M |
| Other Working Capital | (11.76M) | 2.98M | 15.54M | 23.21M | (15.35M) |
| Other Non-Cash Items | 187K | (2.05M) | (14.06M) | (12.45M) | (5.75M) |
| Operating Cash Flow | 29.13M | (133.68M) | (160.6M) | (274.9M) | (322.98M) |
| Capital Expenditures | (129K) | (225K) | 0 | 0 | (187K) |
| Acquisitions (Net) | 40.74K | 225K | 0 | 0 | 0 |
| Purchases of Investments | (294.72M) | (495.35M) | (354.61M) | (557.05M) | (195.81M) |
| Sales of Investments | 253.98M | 308.93M | 472.22M | 337.28M | 486.03M |
| Other Investing Activities | (40.74K) | 225K | 0 | 0 | 0 |
| Investing Cash Flow | (40.87M) | (186.19M) | 117.61M | (219.78M) | 290.04M |
| Debt Repayment | 0 | (21M) | 0 | 0 | 0 |
| Common Stock Issued | 86.34M | 181.39M | 258.09M | 9.72M | 13.68M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 32.13M | 11.86M | 6.04M | 343.65M | 0 |
| Financing Cash Flow | 118.46M | 172.25M | 264.13M | 353.37M | 13.68M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 106.72M | (147.61M) | 221.14M | (141.31M) | (19.27M) |
| Free Cash Flow | 29M | (133.9M) | (160.6M) | (274.9M) | (323.17M) |
Syndax Pharmaceuticals, Inc.
NASDAQ:SNDX
Intrinsic Alpha fair value
Locked
Current Price
$8.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.